HEALTH OF WOMAN. 2019.3(139): 77–80; doi 10.15574/HW.2019.139.77

Garashova M. A.
Azerbaijan Medical University, Baku

The objective: to determine the structure, the stage of detecting ,the severity of subjective manifestations in the presence of tumor processes of the reproductive organs.

Materials and methods. A retrospective analysis of case histories of 301 patients with tumors of the reproductive organs in the postmenopausal period was carried out. The average age of patients was 61.6±0.4 years. The duration of the postmenopausal period ranged from 11.0±0.6 years.

Results. It was established that 28.9% of postmenopausal women have uterine fibroids, 29.4% have endometrial hyperplasia, 21.6% have endometrial cancer, 10.6% – ovarian cancer, 5.6% – benign ovarian tumors, 5.6% – cervical cancer, 1.7% of patients have uterine sarcoma.

In 68.8% of patients, ovarian cancer is diagnosed in the late stages with a predominance of disease detection at stage III of the tumor process (62.5%). Endometrial cancer is diagnosed in 86.2% of patients in the early stages of the tumor process. The frequency of diagnosis of endometrial cancer in the later stages is 4.6%.

From the clinical manifestations of genital tumors in postmenopausal, vaginal bloody discharge and/or bleeding, abdominal pain, rapid heartbeat and excessive body hair growth predominate.

Conclusion. The results obtained allowed to establish that the postmenopausal period is a period of high risk for the development of neoplastic processes of the reproductive organs.

Key words: genital tumors, postmenopausal period, endometrial cancer, ovarian cancer, uterine myoma, uterine sarcoma, endometrial hyperplasia.

REFERENCES

1. Bochkareva NV, Kolomiets LA, Kondakova IV, Muntyan AB. 2009. Otsenka riska razvitiya raka endometriya u bolnyih s giperplasticheskimi protsessami endometriya i miomoy matki v razlichnyie vozrastnyie periodyi. Zhurn. «Opuholi zhenskoy reproduktivnoy sistemy» 1: 102–107.

2. Davyidov AI, Kryizhanovskaya OV. 2009. Giperplasticheskie protsessyi endometriya: kontseptualnyie voprosyi diagnostiki i lecheniya. Voprosyi ginekologii, akusherstva i perinatologii 8;2: 77–82.

3. Klinyishkova TV, Frolova NB, Mozgovoy SI. 2010. Kliniko-morfologicheskoe obosnovanie optimizatsii lecheniya bolnyih s giperplaziey endometriya. Rossiyskiy vestnik akushera-ginekologa 3:16–20.

4. Baird DD, Hill MC, Schectman JM, Hollis BW. 2013. Vitamin D and the risk of uterine fibroids. Epidemiology 24: 447–453. https://doi.org/10.1097/EDE.0b013e31828acca0; PMid:23493030 PMCid:PMC5330388

5. Bowden W, Skorupski J, Kovanci E, Rajkovic A. 2009. Detection of novel copy number variants in uterine leiomyomas using high resolution SNP arrays. Molec. Hum. Reprod. 15;9:563–568. https://doi.org/10.1093/molehr/gap050; PMid:19567454 PMCid:PMC2725754

6. Brinton LA, Sakoda LC, Lissowska J, Sherman ME, Chatterjee N. 2007. Reproductive risk factors for endometrial cancer among Polish women. Br.J.Cancer. 96: 1450–1456. https://doi.org/10.1038/sj.bjc.6603731; PMid:17426703 PMCid:PMC2360184

7. Hildebrand JS, Gapstur SM, Feigelson HS, Teras LR. 2010. Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen. Int.J.Cancer. 127: 2928–2935. https://doi.org/10.1002/ijc.25515; PMid:21351271

8. Kho KA, Lin K, Hechanova M, Richardson DL. 2016. Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Bening Indications. Am.J.Obstet.Gynecol. 127;3: 468–473. https://doi.org/10.1097/AOG.0000000000001242; PMid:26855091 PMCid:PMC5817881

9. Laughlin SK, Schroeder JC, Baird DD. 2010. New directions in the epidemiology of uterine fibroids. Seminars in Reproductive Medicine 28;3: 204–217. https://doi.org/10.1055/s-0030-1251477; PMid:20414843 PMCid:PMC5330647

10. Lieng M, Qvigstad E, Sandvik L et al. 2007, Apr. Hysteroscopic resection of symptomatic and asymptomatic endometrial polyps. J.Minim Invasive Gynecol. 14 (2):189–94. https://doi.org/10.1016/j.jmig.2006.09.018; PMid:17368255

11. Lu L, Risch H, Irwin ML, Mayne ST. 2011. Long-term overweight and weight gain in early adulthood in association with risk of endometrial cancer. Int.J.Cancer. 129: 1237–1243. https://doi.org/10.1002/ijc.26046; PMid:21387312 PMCid:PMC3125463

12. Ma X, Zhao LG, Sun JW, Yang Y. 2015. Association between breastfeeding and risk of endometrial cancer: a meta-analysis of epidemiological studies. Eur.J.Cancer.Prev.

13. Pennant ME, Mehta R, Moody P, Hackett G, Prentice A. 2017. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 124: 404–411. https://doi.org/10.1111/1471-0528.14385; PMid:27766759 PMCid:PMC5297977

14. Saldana TM, Moshesh M, Barid DD. 2013. Self-reported family history of leiomyoma: not a reliable marker of high risk. Annals of Epidemiology 23;5: 286–290. https://doi.org/10.1016/j.annepidem.2013.03.003; PMid:23621994 PMCid:PMC5384608

15. Wu AH, Pearce CL, Tseng CC, Templeman C. 2009. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int.J.Cancer. 124: 1409–1415. https://doi.org/10.1002/ijc.24091; PMid:19065661 PMCid:PMC4203374